Impact of chemoradiotherapy-induced anemia on survival in uniformly staged patients with locally advanced squamous cell carcinoma of the esophagus

Onkologie

Volumn 27, Issue 5, 2004, Pages 462-466

  Hofheinz, R D ^a,d   Raab, B ^a   Mai, S ^b   Wenz, F ^b   Willeke, F ^c   Emig, M ^a   Buchheidt, D ^a   Hehlmann, R ^a   Hochhaus, A ^a  

^a III Medizinische Klinik   (Germany)

^b Inst für Klinische Radiologie   (Germany)

^c MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemoradiotherapy; Esophagus; Hemoglobin; Prognostic factor; Squamous cell carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BARIUM ENEMA; BEAM THERAPY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LUNG EMBOLISM; MALE; MEDIASTINITIS; MUCOSA INFLAMMATION; NEUTROPENIA; PNEUMONIA; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; WOUND HEALING IMPAIRMENT;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CAUSALITY; CISPLATIN; COMBINED MODALITY THERAPY; COMORBIDITY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GERMANY; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 10844223502     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080366     Document Type: Article

References (27)

1. Billingsley KG, Maynard C, Schwartz DL, Dominitz JA: The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Patient survival and outcome analysis. Cancer 2001;92:1272-1280.
2. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003;349:2241-2250.
3. Wenz F, Mamon H: Perioperative radiotherapy for cancer of the esophagus. Sem Surg Oncol 2001;20:33-39.
4. Medical Research Council Oesophageal Cancer Working Party: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002;359:1727-1733.
5. Bedenne L, Michel P, Bouche O, Triboulet JP, Conroy T, Pezet D, Roullet B, Seitz JF, Lacourt J, Milan C: Randomized phase III trial in locally advanced esophageal cancer: Radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc Am Soc Clin Oncol 2002;21:519(abstr.).
6. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T: Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003;238:197-202.
7. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M: In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998;77:1704-1709.
8. Polee MB, Hop WCJ, Kok TC, Eskens FALM, van der Burg MEL, Splinter TAW, Siersema PD, Tilanus HW, Stoter G, van der Gast A: Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 2003;89:2045-2050.
9. Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M, Dunst J: Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000;465:459-466.
10. Bush RS, Jenkin RD, Allt D, Beale FA, Bean H, Dembo AJ, Pringle JF: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978;37(Suppl):302-306.
11. Koehne CH, Cunningham D, Di Costanzo CF, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-317.
12. Taussky D, Rousson V, Pescia R: Clinical markers of hypoxia and other predictive factors of survival in conservative therapy of squamous-cell carcinoma of the esophagus. Int J Colorectal Dis 2003;18:167-171.
13. Schäfer U, Micke O, Müller SB, Schüller P, Willich N: Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-534.
14. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
15. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen G: Anemia in cervical cancers: Impact on survival patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003;56:778-787.
16. Craig SR, Adam DJ, Yap PL, Leaver HA, Elton RA, Cameron EWJ, Sang CTM, Walker WA: Effect of blood transfusion on survival after esophagogastrectomy for carcinoma. Ann Thorac Surg 1998;66:356-361.
17. Langley SM, Alexiou C, Bailey DH, Weeden DF: The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma. Ann Thorac Surg 2002;73:1704-1709.
18. Blumberg N, Heal JM: The transfusion immunomodulation theory: The Th1/Th2 paradigm and an analogy with pregnancy as a unifying mechanism. Semin Hematol 1996;33:329-340.
19. Lavey RS, Dempsey WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:1147-1152.
20. Case DC Jr., Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW, Nichols CR: Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-806.
21. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
22. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
23. Tsuji Y, Kambayashi JI, Shiba E, Sakon M, Kawasaki T, Mori T: Effect of recombinant human erythropoietin on anaemia after gastrectomy: A pilot study. Eur J Surg 1995;161:29-33.
24. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Neer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind placebo-controlled trial. Lancet 2003;362:1255-1260.
25. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H: Erythropoietin regulates tumor growth of human malignancies. Carcinogenesis 2003;24:1021-1029.
26. Haq R, Halupa A, Beattie BK, Mason JM, Zanke BW, Barber DL: Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem 2002;277:17359-17366.
27. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK: Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514-1520.